22nd Century Group CEO
to speak at tobacco forum
22nd Century Group Inc., a plant biotechnology company with a production plant in Mocksville, said that Henry Sicignano III, its chief executive, will speak at today's Global Tobacco & Nicotine Forum in New York City.
Sicignano will participate on a panel discussing future next-generation products.
The forum is noted for its exchange of global ideas and information for tobacco technologies and products. Attendees to the forum include public health advocates, policymakers, scientists and industry executives.
22nd Century, based in Clarence, N.Y., bought the cigarette-manufacturing equipment of defunct Renegade Tobacco Co. in 2013 for $3.22 million in a bankruptcy proceeding.
Triad HealthCare Network adds medical directors
Triad HealthCare Network said Wednesday it has added Drs. Beth Hodges and Rob Reade as medical directors to its primary care division.
The network is a partnership between area health-care providers and Cone Health.
Cone said the doctors will provide "a physician's perspective in developing the network's various quality and savings initiatives."
Hodges is a family medicine doctor at Hodges Family Practice in Asheville. Reade is a family medicine doctor at Eagle Family Medicine @ Triad. Both will continue seeing patients.
Lexington Dialysis Center gets state OK for facility
Lexington Dialysis Center has received conditional approval from state health regulators for its certificate-of-need application.
The group has applied to spend $4.72 million on building a new facility on the same site at 233 Anna Lewis Drive.
The group is affiliated with Wake Forest Baptist Medical Center.
High Point pharmaceutical company plans IPO
Axium Pharmaceuticals Inc., based in High Point, has submitted a regulatory filing for a proposed initial public offering of its Class A common stock.
The company plans to sell 50 million shares, while shareholders plan to sell 45.13 million shares. There is no underwriter of the IPO.
The asking price is projected to be 10 cents a share, with potential gross proceeds of $9.51 million, including $5 million for use by the corporation.
Axium focuses on utilizing drug delivery innovations for developing improved novel formulations and alternative dosage forms of existing biologically active molecules. Product candidates address various pharmaceutical markets, including neurological disorderss, infectious diseases and diabetes.
© © Copyright 2017, Winston-Salem Journal, Winston-Salem, NC, source Newspapers